References
1. Christ, E., et al., Insulinomatosis: new aspects. Endocr Relat Cancer, 2023. 30 (6).2. Okabayashi, T., et al., Diagnosis and management of insulinoma. World J Gastroenterol, 2013.19 (6): p. 829-37.3. Tesfaye, N. and E.R. Seaquist,Neuroendocrine responses to hypoglycemia. Ann N Y Acad Sci, 2010.1212 : p. 12-28.4. Câmara-de-Souza, A.B., et al.,Insulinoma: A retrospective study analyzing the differences between benign and malignant tumors. Pancreatology, 2018.18 (3): p. 298-303.5. Sada, A., et al., Comparison of benign and malignant insulinoma. Am J Surg, 2021. 221 (2): p. 437-447.6. Zhao, Y., et al., Analysis of 55 patients with multiple endocrine neoplasia type 1-associated insulinoma from a single center in China. Orphanet J Rare Dis, 2022. 17 (1): p. 219.7. Kittah, N.E. and A. Vella, MANAGEMENT OF ENDOCRINE DISEASE: Pathogenesis and management of hypoglycemia. Eur J Endocrinol, 2017.177 (1): p. R37-r47.8. Hirshberg, B., et al.,Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab, 2000. 85 (9): p. 3222-6.9. Crinò, S.F., et al., Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma. Clin Gastroenterol Hepatol, 2023. 21 (11): p. 2834-2843.e2.10. Mele, C., et al., Non-surgical ablative therapies for inoperable benign insulinoma. J Endocrinol Invest, 2018. 41 (2): p. 153-162.11. Qu, Y., et al., Clinical Characteristics and Management of Functional Pancreatic Neuroendocrine Neoplasms: A Single Institution 20-Year Experience with 286 Patients. Int J Endocrinol, 2020.2020 : p. 1030518.12. Etchebehere, E.C., et al.,68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J Nucl Med, 2014. 55 (10): p. 1598-604.13. Maggio, I., et al., The functioning side of the pancreas: a review on insulinomas. J Endocrinol Invest, 2020. 43 (2): p. 139-148.
Table1 Glucose tolerance test, C-peptide and insulin release tests